Jahnz-Rózyk Karina, Targowski Tomasz, From Sławomir
Zakład Immunologii i Alergologii Klinicznej Wojskowego Instytutu Medycznego w Warszawie Kierownik.
Pneumonol Alergol Pol. 2008;76(6):426-31.
The aim of the study was to examine the direct and indirect costs of COPD exacerbations under usual clinical practice in primary and secondary care from a societal perspective in Poland.
An observational, prospective study was conducted among patients with exacerbation of moderate or severe COPD. Seventy-three patients were included in the study - 39 treated in hospital (HC) and 34 treated in ambulatory care (AC). The direct costs included the cost of drugs, diagnostic tests, in-hospital and outpatient care. The indirect costs included costs of transportation to the health-care provider and work days lost.
The mean duration of COPD exacerbation did not differ significantly between the groups [HC: 11.2 (CI 95%: 9.6-12.8) days; AC: 10.8 (CI 95%: 9.1-12.1); p > 0.05]. The total health-care cost per exacerbation was EUR 1197 (4137.9 PLN) in secondary care (the HC group), and it was 6 times higher than the total cost of exacerbation in primary care (the AC group) - EUR 199.8 (446.9 PLN). The costs of drugs and diagnostic tests were significantly higher in the HC group than in the AC group; however, it was the cost of in-hospital stay and medical visits in the HC group that most influenced expenditure related to COPD exacerbations, as they were 27 times higher than in the AC group.
In Poland the costs of COPD exacerbation managed in secondary care are 6-fold higher than in primary care. Therefore, the decisions about admission of patients with COPD exacerbation to hospital should be made carefully.
本研究旨在从波兰社会角度,考察在初级和二级医疗常规临床实践中慢性阻塞性肺疾病(COPD)急性加重的直接和间接成本。
对中重度COPD急性加重患者进行了一项观察性前瞻性研究。73例患者纳入研究,其中39例在医院治疗(HC组),34例在门诊治疗(AC组)。直接成本包括药物、诊断检查、住院和门诊护理费用。间接成本包括前往医疗服务提供者的交通费用和误工天数。
两组间COPD急性加重的平均持续时间无显著差异[HC组:11.2(95%CI:9.6 - 12.8)天;AC组:10.8(95%CI:9.1 - 12.1);p > 0.05]。二级医疗(HC组)中每次急性加重的总医疗成本为1197欧元(4137.9波兰兹罗提),比初级医疗(AC组)中急性加重的总成本高6倍 - 199.8欧元(446.9波兰兹罗提)。HC组的药物和诊断检查成本显著高于AC组;然而,HC组的住院费用和医疗就诊费用对COPD急性加重相关支出影响最大,因为它们比AC组高27倍。
在波兰,二级医疗中管理COPD急性加重的成本比初级医疗高6倍。因此,对于COPD急性加重患者是否入院的决策应谨慎做出。